| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 0 | 450.065 | 478.851 | 803.324 | 849.386 | 515.880 |
| Total Income - EUR | - | - | - | - | 42 | 452.335 | 490.785 | 832.233 | 883.575 | 524.417 |
| Total Expenses - EUR | - | - | - | - | 1.570 | 32.592 | 40.963 | 154.874 | 528.758 | 311.581 |
| Gross Profit/Loss - EUR | - | - | - | - | -1.528 | 419.743 | 449.822 | 677.358 | 354.817 | 212.836 |
| Net Profit/Loss - EUR | - | - | - | - | -1.529 | 415.506 | 443.608 | 670.534 | 328.264 | 181.362 |
| Employees | - | - | - | - | 0 | 1 | 1 | 2 | 1 | 0 |
Check the financial reports for the company - Regpak Biopharma Consulting S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 13.677 | 1.628 | 1.619 |
| Current Assets | - | - | - | - | 200 | 422.178 | 863.320 | 1.568.257 | 1.866.496 | 1.997.507 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 138 | 253.661 | 234.667 | 385.726 | 598.263 | 713.948 |
| Cash | - | - | - | - | 62 | 168.518 | 628.653 | 1.182.530 | 1.268.233 | 1.283.559 |
| Shareholders Funds | - | - | - | - | -1.487 | 414.047 | 848.473 | 1.521.639 | 1.795.287 | 1.950.460 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 1.687 | 8.429 | 14.951 | 60.391 | 72.836 | 48.665 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7210 - 7210" | |||||||||
| CAEN Financial Year |
7219
|
|||||||||
Comments - Regpak Biopharma Consulting S.r.l.